Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2...
Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2...
Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Year-End 2024 Or Early Q1 2025
Cybin就即將到來的臨床里程碑提供了企業更新；預計將在近期啓動關鍵性CYB003第3期研究，用於重性抑鬱障礙；預計將在2024年第4季度初公佈CYB003用於MDD的12個月療效數據；預計將於2024年年底或2025年初第1季度公佈CYB004用於廣泛性焦慮障礙的第2期前期療效和安全性結果
- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder ("MDD") expected imminently -
- 預計將即將啓動關鍵性CYB003第3期研究，用於重性抑鬱障礙（"MDD"） -
- 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 -
- 預計將在2024年第4季度初公佈CYB003用於MDD的12個月療效數據 -
- Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder ("GAD") expected year-end 2024 or early Q1 2025 -
- 預計將於2024年年底或2025年初第1季度公佈CYB004用於廣泛性焦慮障礙（"GAD"）的第2期前期療效和安全性結果 -
- Strengthened R&D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively -
- 通過增加經驗豐富的藥物研發領導者Dr. Atul R. Mahableshwarkar和Dr. Tom Macek來加強研發團隊，分別作爲CYB003和CYB004項目的負責人 -
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones.
Cybin公司（紐交所:CYBN）（Cboe CA:CYBN）（"Cybin"或"公司"），一家臨床階段的突破性神經精神病學公司，致力於通過開發新的創新性下一代治療方案，徹底改變精神保健，今天報告了最近的臨床成就和重要即將到來的臨床里程碑。
譯文內容由第三人軟體翻譯。
